Clareo Health | A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
First line of the email MUST contain NCT # and Site #.
CONTACT
Lead
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have been treated in the post-marketing setting with at least 1 infusion of lisocabtagene maraleucel (liso-cel) used for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL), including FL Grade 1, Grade 2 and Grade 3a, within the FDA-approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA
You may not be if
Participants known to be participating in investigational studies at the time of liso-cel, infusion
Participants treated with liso-cel for the treatment of R/R FL Grade 3b
Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product
